CoChat

RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC)

Open access
Ezzeldin, Mohamad, Borrego-Diaz, Emma, Taha, Mohammad, Esfandyari, Tuba, Wise, Amanda L., Peng, Warner, Rouyanian, Alex, Asvadi Kermani, Atabak, Soleimani, Mina, Patrad, Elham, Lialyte, Kristina, Wang, Kun, Williamson, Stephen, Abdulkarim, Bashar, Olyaee, Mojtaba, Farassati, Faris · 2014 · Molecular Oncology
Cited by 46

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Ral (Ras like) leads an important proto‐oncogenic signaling pathway down‐stream of Ras. In this work, RalA was found to be significantly overactivated in hepatocellular carcinoma (HCC) cells and tissues as compared to non‐malignant samples. Other elements of RalA pathway such as RalBP1 and RalGDS were also expressed at higher levels in malignant samples. Inhibition of RalA by gene‐specific silencing caused a robust decrease in the viability and invasiveness of HCC cells. Additionally, the use of geranyl–geranyl transferase inhibitor (GGTI, an inhibitor of Ral activation) and Aurora kinase inhibitor II resulted in a significant decrease in the proliferation of HCC cells. Furthermore, RalA activation was found to be at a higher level of activation in HCC stem cells that express CD133. Transgenic mouse model for HCC (FXR‐Knockout) also revealed an elevated level of RalA‐GTP in the liver tumors as compared to background animals. Finally, subcutaneous mouse model for HCC confirmed effectiveness of inhibition of aurora kinase/RalA pathway in reducing the tumorigenesis of HCC cells in vivo. In conclusion, RalA overactivation is an important determinant of malignant phenotype in differentiated and stem cells of HCC and can be considered as a target for therapeutic intervention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molonc.2014.03.020

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 46

Metadata

Authors
Ezzeldin, M., Borrego-Diaz, E., Taha, M., Esfandyari, T., Wise, A. L., Peng, W., Rouyanian, A., Asvadi Kermani, A., Soleimani, M., Patrad, E., Lialyte, K., Wang, K., Williamson, S., Abdulkarim, B., Olyaee, M., & Farassati, F.
Venue
Molecular Oncology
Publisher
Wiley
Published
2014-04-13
Volume
8
Issue
5
Pages
1043-1053
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W2089695492
Cited by
46
References
2
FWCI
1.58
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC). https://app.cochat.ai/papers/10.1016/j.molonc.2014.03.020
The paper
Ezzeldin, M., Borrego-Diaz, E., Taha, M., Esfandyari, T., Wise, A. L., Peng, W., Rouyanian, A., Asvadi Kermani, A., Soleimani, M., Patrad, E., Lialyte, K., Wang, K., Williamson, S., Abdulkarim, B., Olyaee, M., & Farassati, F. (2014). RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC). Molecular Oncology. https://doi.org/10.1016/j.molonc.2014.03.020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.